Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


SAGE Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

September 22, 2017
Sage Therapeutics to Participate in Leerink Investor Conference

September 12, 2017
Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus

September 7, 2017
Sage Therapeutics to Present at Morgan Stanley Healthcare Conference

Read More News

Associated Team Members

Kevin Starr
Partner